CAM5.2低分子細(xì)胞角蛋白（鼠單克隆抗體）

廣州健侖生物科技有限公司

細(xì)胞角蛋白是一種常用的腫瘤免疫組織化學(xué)標(biāo)記物，陽(yáng)性表達(dá)見(jiàn)于上皮細(xì)胞、間皮細(xì)胞；癌間皮瘤等。細(xì)胞角蛋白（cytokeratin CK）主要分布于上皮細(xì)胞，是角質(zhì)細(xì)胞中的主要骨架蛋白，這種結(jié)構(gòu)蛋白的主要功能是維持上皮組織的完整性及連續(xù)性。研究發(fā)現(xiàn)細(xì)胞角蛋白（CK）具有*的保守性和組織分化特異性，與上皮細(xì)胞的增殖分化密切相關(guān)。目前已得到證實(shí)的細(xì)胞角蛋白有20多種。

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢(xún)

歡迎咨詢(xún)

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞漿

克隆號(hào)：CAM5.2

適用組織：石蠟/冰凍

陽(yáng)性對(duì)照：直腸癌/肺腺癌

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時(shí)間：30-60min

CAM5.2低分子細(xì)胞角蛋白（鼠單克隆抗體）

預(yù)防以自動(dòng)免疫為主，在我國(guó)常用白百破（白喉類(lèi)毒素、百日咳桿菌Ⅰ相滅活菌苗、破傷風(fēng)類(lèi)毒素，DPT）三聯(lián)菌苗，接種對(duì)象為一歲以下幼兒。接種后能顯著降低發(fā)病率和死亡率。但目前使用的死菌苗在一定的副作用，在安全性、免疫原性方面均有進(jìn)一步改進(jìn)的必要。
治療可用紅霉素、氨芐青毒素等。 百日咳桿菌
急性傳染病百日咳的病原菌。
1906年，比利時(shí)細(xì)菌學(xué)家和免疫學(xué)家鮑臺(tái)和讓古發(fā)現(xiàn)，又稱(chēng)鮑--讓桿菌。他們同時(shí)發(fā)明了百日咳桿菌菌苗。他們?cè)谘芯恐邪l(fā)現(xiàn)，百日咳桿菌含有對(duì)熱不穩(wěn)定物質(zhì)，將其注入豚鼠和家兔腹腔或靜脈中，能將動(dòng)物殺死。如給皮下注射則產(chǎn)生皮膚壞死。從有病的孩子臨床表現(xiàn)以及百日咳菌苗的副作用等均表明百日咳桿菌具有特殊的致病物質(zhì)。以后許多學(xué)者從各個(gè)側(cè)面研究百日咳桿菌的致病物，又陸續(xù)發(fā)現(xiàn)該菌含有多種生物學(xué)活性物質(zhì)，其中有些物質(zhì)與治病作用密切相關(guān)。近年來(lái)，日本、美國(guó)等許多學(xué)者已經(jīng)研究制備百日咳無(wú)細(xì)胞菌苗代替全細(xì)胞菌苗，可顯著減低全細(xì)胞菌苗的毒性反應(yīng)。由于百日咳是一種常見(jiàn)的呼吸道感染病，所以應(yīng)廣泛地進(jìn)行百日咳菌苗預(yù)防接種，一般新生兒生后三個(gè)月即可注射百日咳菌苗。由于百日咳菌苗的毒性反應(yīng)使特異預(yù)防受到限制，應(yīng)加速研抗原抗體性低免疫效果好的無(wú)細(xì)胞菌苗
病因
由剛地弓形蟲(chóng)所引起，呈流行。特殊人群如腫瘤患者、免疫抑制或免疫缺陷患者、先天性缺陷嬰幼兒感染率較高。
臨床表現(xiàn)
一般分為先天性和后天獲得性?xún)深?lèi)，均以隱抗原抗體染為多見(jiàn)。臨床癥狀多由新近急抗原抗體染或潛在病灶活化所致。
先天性弓形蟲(chóng)病的臨床表現(xiàn)復(fù)雜。多數(shù)嬰兒出生時(shí)可無(wú)癥狀，其中部分于出生后數(shù)月或數(shù)年發(fā)生視網(wǎng)膜脈絡(luò)膜炎、斜視、失明、癲癇、精神運(yùn)動(dòng)或智力遲鈍等。下列不同組合的臨床表現(xiàn)：視網(wǎng)膜脈絡(luò)膜炎、腦積水、小頭畸形、無(wú)腦兒、顱內(nèi)鈣化等應(yīng)考慮本病可能。

CAM5.2

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱(chēng)】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

Prevention of autoimmune mainly diphtheria broken (diphtheria toxoid, B. pertussis phase I inactivated vaccine, tetanus toxoid, DPT) triple bacterins commonly used in our country, vaccinated objects for children under one year of age. Inoculation can significantly reduce morbidity and mortality. However, the current use of dead bacterin in some side effects, both in terms of safety, immunogenicity have the need for further improvement.
Erythromycin can be used for treatment, such as ampicillin. Bordela pertussis
Acute infectious disease Pertussis pathogens.
In 1906, the Belgian bacteriologist and immunologist Bao Tai and Jean ancient found, also known as abalone - let bacillus. They also invented the Bordela pertussis vaccine. In their study, they found that Bordela pertussis contains a heat-labile substance that can be injected into the abdominal cavity or vein of guinea pigs and rabbits to kill the animal. Skin subcutaneous injection can cause skin necrosis. From the clinical manifestations of sick children and the side effects of pertussis vaccine, etc. have shown that Bordela pertussis has a special pathogenic substances. Since then, many scholars have studied the pathogens of Bordela pertussis from various aspects and have successively discovered that the bacterium contains many kinds of biological active substances. Some of these substances are closely related to the therapeutic effect. In recent years, Japan, the United States and many other scholars have studied the preparation of acellular pertussis acellular vaccine instead of whole cell vaccine can significantly reduce the toxicity of whole cell vaccine. Because of whooping cough is a common respiratory disease, it should be carried out widely vaccination pertussis vaccine, the general neonatal three months after birth can be injected pertussis vaccine. Due to the pertussis vaccine toxicity response to specific prevention is limited, should accelerate the research of antigen-antibody low immune effect of acellular cell vaccine
Etiology
Toxoplasma gondii caused by the global epidemic. Special populations such as cancer patients, immunosuppressed or immunodeficient patients, high incidence of congenital infantile infection.
Clinical manifestations
Generally divided into two types of acquired congenital and acquired are hidden anti-antigen antibody is more common. Clinical symptoms and more by the recent acute antigen antibody staining or potential lesions caused by activation.
The clinical manifestations of congenital toxoplasmosis are complex. Most babies are asymptomatic at birth, and some of them occur retinal choroiditis, strabismus, blindness, epilepsy, mental retardation, mental retardation, etc. months or years after birth. The following different combinations of clinical manifestations: retinal choroiditis, hydrocephalus, microcephaly, no brain, intracranial calcification, etc. should consider the possibility of this disease.